Ikena is a publicly traded company that is advancing multiple clinical-stage targeted oncology treatments.
Ikena is focused on developing novel therapies that target the key signaling pathways that drive the formation and spread of cancer. We are advancing multiple programs that target tumor markers, as well as programs that target the tumor microenvironment. Our lead program, IK-930, is a TEAD inhibitor targeting the Hippo signaling pathway, a pathway that can drive the formation and increase the survival of tumors and can also fuel resistance to multiple existing therapies. Additional programs include those targeting the RAS signaling pathway and several programs targeting the tumor microenvironment and immune signals, one of which is being developed in collaboration with Bristol Myers Squibb. Ikena’s pipeline is built on targeting genetically defined or biomarker-driven cancers and developing therapies that can serve specific patient populations in need of new therapeutic options.

Heading H1

Heading H2

Heading H3

This is the body text style. Lorem ipsum dolor sit amet, consectetur adipiscing elit. Suspendisse in faucibus sapien, accumsan vehicula odio. Maecenas interdum commodo imperdiet. Aliquam velit metus, ultricies vel sem ultrices, suscipit aliquet lorem. Nunc molestie aliquam erat, eu facilisis ex auctor ac. Nulla ullamcorper tincidunt porta. Vestibulum id luctus ante. Sed ut nisl ultrices sapien suscipit sollicitudin. Nullam ornare consectetur velit, ornare ultrices ex pharetra vitae. Nunc pulvinar hendrerit enim nec egestas. Duis quis mi vestibulum, sollicitudin leo et, luctus neque. Etiam iaculis nunc eget quam fringilla, sed malesuada ex rutrum. Nulla non dui in ex dignissim sagittis. Nam ac libero enim. Quisque tempor aliquam purus ac sollicitudin. Nam eu posuere arcu, at rhoncus dui.

Scroll to Top